Eloralintide is an investigational, once-weekly injectable amylin analogue from Eli Lilly, designed to be more selective than cagrilintide with the goal of producing similar weight loss with less nausea. In its phase 2 trial it reached up to 20.1 percent weight loss at 48 weeks, but that figure comes from an “efficacy estimand” that assumes perfect adherence, not the trial’s plain result. More importantly, its central selling point, better tolerability, is not clearly supported by its own data: nausea reached 64 percent in one dose arm, at or above rates reported for the very drug it was designed to improve on. It is not approved anywhere and no phase 3 trial has reported.
Ask about Eloralintide
Research snapshot
| Category | Current information |
|---|---|
| Peptide category | Amylin receptor agonist (investigational, AMY1R-selective) |
| Primary research interest | Obesity and weight management (phase 3); type 2 diabetes (phase 2) |
| Highest available evidence | Published human clinical trial (phase 1 SAD/MAD and phase 2 obesity data, peer-reviewed) |
| Human research available | Yes, limited: phase 1 and phase 2 results published; the six-trial ENLIGHTEN phase 3 program is registered but unreported, and the two-trial AMPLIFY phase 3 program for the eloralintide and tirzepatide combination is registered, with AMPLIFY-2 listed as recruiting and AMPLIFY-1 not yet recruiting |
| Development status | Investigational, phase 3 (Eli Lilly, development code LY3841136) |
| Regulatory status | Not approved, not filed for approval, not available outside sponsor-run clinical trials |
Technical identity
| Technical property | Information |
|---|---|
| Primary name | Eloralintide |
| Alternative names | LY3841136 (Eli Lilly development code) |
| Peptide sequence | Not disclosed by the sponsor. No Lilly publication or registration gives a full sequence, and because three residues are non-coded, a conventional single-letter string could not fully describe the molecule even if the backbone were known. Any source printing a specific 37-letter sequence is printing something the sponsor has not released. |
| Amino-acid length | 37 residues (reported chain length; three are non-coded and the exact sequence is undisclosed) |
| Molecular formula | C201H319N49O65S2: from chemical-supplier catalog listings only (BPS Bioscience, AbMole BioScience, A2B Chem); not confirmed against a peer-reviewed or regulatory source |
| Molecular weight | 4526.10 g/mol: same supplier-only sourcing; not independently verified |
| CAS Registry Number | 2883634-40-8: same supplier-only sourcing; not independently verified |
| PubChem CID | Not established |
| Chemical modifications | Methylene-thioacetal bridge in place of the native disulfide; C20 fatty diacid conjugated at lysine 26 for albumin binding, giving a reported half-life of roughly 12.9-15.3 days |
| Peptide class | Amylin analog / amylin-receptor (AMY1R) agonist |
| Primary biological target | Amylin 1 receptor (AMY1R); reported roughly 12-fold more potent at AMY1R than the calcitonin receptor and roughly 11-fold more potent than at AMY3R in human cell assays |
| Developer or originator | Eli Lilly and Company |
| Development status | Phase 3 (ENLIGHTEN clinical program) |
What it is
Eloralintide, development code LY3841136, is an investigational once weekly injectable peptide from Eli Lilly, a synthetic analogue of human amylin, the hormone co secreted with insulin that slows gastric emptying and signals satiation through the hindbrain. It is not approved anywhere and no marketing application has been filed.
Briere 2025 in Molecular Metabolism gives the only public structural description: a main chain of 37 amino acids, the length of native amylin, with three non coded residues at positions 11, 15 and 22, the native disulfide replaced by a methylene thioacetal bridge, and a C20 fatty diacid at lysine 26 that binds albumin and gives a half life of 12.9 to 15.3 days.
Lilly has not published the sequence. Any page printing a clean 37 letter string is printing something the sponsor never released, and with three residues non coded, no letter string could describe the molecule anyway. The molecular weight, formula and CAS number in circulation come only from chemical supplier catalogues, which copy one another.
The selectivity thesis, and how much evidence it has
Amylin receptors form when the calcitonin receptor, CTR, pairs with a receptor activity modifying protein, giving AMY1R and AMY3R, so every amylin analogue engages CTR to some degree. The hypothesis is that CTR engagement in the hindbrain recruits aversive signalling rather than satiation, so sparing it might give the same weight loss with less nausea.
Briere 2025 reports human cAMP EC50 values of 23.9 pM at AMY1R, 253.8 pM at AMY3R and 291.0 pM at CTR, roughly 12 fold more potent at the amylin 1 receptor than at the calcitonin receptor. Cagrilintide, in the same assays, activates all three comparably.
What the margin does not mean is usually lost. Eloralintide reached full agonism at all three human receptors, maximum efficacy above 80 percent at each. It is not a partial agonist or blocker at the calcitonin receptor, only less potent, so at sufficient exposure CTR is engaged.
The tolerability case rests on two rodent experiments. In conditioned taste avoidance in lean rats, eloralintide had an ED50 of 8.9 nmol/kg against 4.2 for cagrilintide, the direction that favours eloralintide. In diet induced obese rats, fat accounted for 80 to 91 percent of the weight it lost against 63 percent for cagrilintide, with significantly less lean mass loss. Both ran in rats, where eloralintide is selective for a different receptor pair: there it is a dual AMY1R and AMY3R agonist selective only against CTR, a different pharmacology from the human one.
Lilly says the rest itself. Its own paper states that “there is no established minimum selectivity threshold to define biologically relevant selectivity,” and offers an alternative: “Differences in potency between eloralintide and cagrilintide could result from differences in PK, particularly the shorter Tmax and half-life of cagrilintide relative to eloralintide.” No head to head human trial exists. Selectivity is the hypothesis phase 3 exists to test, not a demonstrated benefit.
What dosage information circulates?
Figures in this table summarize amounts and schedules studied in Eli Lilly’s registered human trials. Eloralintide’s amino-acid sequence has not been disclosed by the sponsor, so no legitimately manufactured version of this molecule exists outside that clinical trial program, and any vial sold online as “eloralintide” cannot be verified as the actual investigational compound. This table therefore does not include vendor or community dosage figures, only doses studied in sponsor-run trials.
| Reported use or research objective | Route reported | Amount reported | Frequency reported | Reported duration | Evidence or source category |
|---|---|---|---|---|---|
| Single ascending-dose safety and pharmacokinetics | Subcutaneous | 0.04-12 mg | Single dose | PK sampled for several weeks post-dose | Published human clinical trial (Briere et al. 2025; NCT05295940, Part A) |
| Multiple ascending-dose safety and PK, obesity/overweight | Subcutaneous | 1.2-12 mg | Weekly | 12 weeks | Published human clinical trial (Bhattachar et al., Diabetes Obes Metab 2026; NCT05295940, Part B) |
| Weight loss, obesity/overweight without type 2 diabetes | Subcutaneous | 1-9 mg | Weekly | 48 weeks | Published human clinical trial (phase 2, 263 participants) |
| Weight loss and HbA1c, obesity/overweight with type 2 diabetes, eloralintide alone | Subcutaneous | 3, 6 or 9 mg (started at 1 or 3 mg, escalated every 4 weeks) | Weekly | 48 weeks | Conference presentation of a human phase 2b trial, via sponsor press release, not peer reviewed (NCT06603571) |
| Same trial, eloralintide combined with tirzepatide (eloraTZP) | Subcutaneous | Eloralintide 3 to 9 mg with tirzepatide 5 to 15 mg, in four fixed pairings | Weekly | 48 weeks | Conference presentation of a human phase 2b trial, via sponsor press release, not peer reviewed (NCT06603571) |
| Weight change, eloralintide with tirzepatide (EloraTZP), phase 3 AMPLIFY-1 (NCT07881432) and AMPLIFY-2 (NCT07881458) | Subcutaneous, per the registry record | Not listed in the registry record | Not listed in the registry record | Primary endpoint at week 100 | Registered but unpublished human trial (AMPLIFY-2 recruiting, AMPLIFY-1 not yet recruiting) |
No dosage from any of the six phase 3 ENLIGHTEN trials has been reported; the earliest primary completion date is January 2028. The AMPLIFY-1 and AMPLIFY-2 records for the eloralintide and tirzepatide combination state that the combination is given subcutaneously but list no dose amounts or schedule. Grey-market vials labeled “eloralintide” are the proximate source of most dosage and sequence claims circulating online, but since the sponsor has never disclosed the sequence, nothing sold outside the trial program can be verified as this molecule.
Potential benefits and research applications
Weight loss with a hoped-for tolerability advantage over other amylin drugs
What is being investigated: whether targeting the amylin receptor more selectively than cagrilintide can produce comparable weight loss with fewer side effects. How the effect might occur: by engaging the calcitonin receptor, thought to drive aversive, nausea-like effects, less than a non-selective amylin agonist does. Evidence: the phase 2 trial reached 20.1 percent weight loss at the top dose on its efficacy estimand. Strength: is being investigated in registered human trials; the underlying weight-loss effect has been shown. Limitation: the tolerability advantage this design was built to prove is not clearly demonstrated by the trial’s own nausea data, and Lilly’s own paper acknowledges there is no established threshold defining what counts as meaningfully selective.
Reduced heart rate, an unusual and unexplained finding
What is being investigated: nothing intentionally, this was an observed effect. How it might occur: unknown; it runs opposite to the heart rate increase typically seen with GLP-1 receptor agonists. Evidence: a phase 1b study found resting pulse fell by up to 14.4 beats per minute at the higher dose over 12 weeks. Strength: has been observed in a controlled human study. Limitation: whether a heart rate drop of that size is clinically meaningful or a safety concern has not been established, and no amylin receptor agonist of any kind has completed a cardiovascular outcomes trial.
Body composition, more fat loss relative to lean mass in animal studies
What is being investigated: whether selective amylin agonism spares more lean tissue during weight loss than a non-selective agonist. How the effect might occur: through the same receptor-selectivity mechanism proposed for tolerability. Evidence: in obese rats, fat accounted for 80 to 91 percent of weight lost against 63 percent for cagrilintide. Strength: has been shown in animal models. Limitation: no human body composition data have been published for eloralintide, so whether this preclinical advantage carries over to people is unknown.
The phase 2 obesity trial
NCT06230523, reported by Billings and colleagues in The Lancet in 2025, randomised 263 adults with obesity or overweight and without type 2 diabetes across seven arms for 48 weeks.
The figures come under the efficacy estimand, which Lilly defines as the efficacy that would have been observed had all randomised participants remained on study intervention for 48 weeks. That is a hypothetical strategy, not a treatment policy result. Quoting 20 percent without it is one of the standard errors about this compound.
On that estimand at week 48: 1 mg minus 9.5 percent, 3 mg minus 12.4, 6 mg minus 17.6, 9 mg minus 20.1, the arm escalated from 6 to 9 mg minus 19.9, the arm escalated through 3 and 6 to 9 mg minus 16.4, and placebo minus 0.4 percent. Placebo lost essentially nothing, where obesity trial placebo arms often lose 2 to 3 percent.
The nausea data undercut the headline
Nausea by arm: 14 percent on placebo, 11 percent at 1 mg, 13 percent at 3 mg, 64 percent at 6 mg, 33 percent at fixed 9 mg, 54 percent in the 6 to 9 mg escalation and 25 percent in the slower escalation. That is not monotonic: the 6 mg arm reported nearly double the rate of the higher fixed 9 mg dose, on 28 and 54 participants respectively.
The highest rates sit at or above the 24 to 31 percent nausea reported for cagrilintide 2.4 mg monotherapy. A compound whose entire thesis is better tolerability reported nausea at or above the compound it was designed to improve on. That is the finding. The low gastrointestinal claim rests on phase 1, where nausea was 8.2 percent over 12 weeks without titration, and 48 weeks of phase 2 qualifies it.
Figures posted but not retrievable
Discontinuation rates by arm, vomiting by arm, serious adverse event counts and responder rates are absent here. The Lancet full text is paywalled and the abstract omits them, while the registry flags results as posted for NCT06230523, so the figures exist and are public. That is a gap in this compilation, not in the evidence.
Heart rate runs backwards to the class
In the 12 week phase 1b study, eloralintide lowered resting pulse dose relatedly: at week 12, minus 3.4 bpm on placebo, minus 8.3 at 6 mg and minus 14.4 bpm at 12 mg. Sigalov and Frishman in Cardiology in Review note the contrast with the heart rate increase associated with GLP-1 receptor agonists. Circulating claims have it inverted. A fall that size is not automatically benign either: the trials exclude bradyarrhythmia and, in the diabetes protocol, a resting pulse below 60 bpm. No amylin receptor agonist has been through a cardiovascular outcomes trial.
Phase 2 in type 2 diabetes: eloralintide alone and with tirzepatide
NCT06603571 is a 48 week, double blind, placebo controlled phase 2b trial in 367 adults with obesity or overweight and type 2 diabetes, run in the United States and Argentina. Lilly presented it at the EASD 2026 meeting in Milan and issued a press release on 30 September 2026. It has not been published in a journal, so everything below is sponsor reported conference data that has not been peer reviewed. Participants started at a mean body weight of 105.4 kg and a mean HbA1c of 8.1 percent.
Every figure uses the efficacy estimand, meaning what would have been seen had everyone stayed on treatment for 48 weeks. No treatment regimen estimand was reported, so these numbers are the favorable version, the same caveat that applies to the obesity trial above.
| Arm (weekly injections) | Weight change, efficacy estimand | HbA1c change |
|---|---|---|
| Eloralintide 3 mg | minus 8.2 percent | minus 1.1 points |
| Eloralintide 6 mg | minus 12.3 percent | minus 1.4 points |
| Eloralintide 9 mg | minus 11.1 percent | minus 1.3 points |
| Tirzepatide 15 mg | minus 14.8 percent | minus 2.4 points |
| Eloralintide 3 mg plus tirzepatide 5 mg | minus 13.2 percent | minus 2.2 points |
| Eloralintide 6 mg plus tirzepatide 5 mg | minus 19.4 percent | minus 2.7 points |
| Eloralintide 6 mg plus tirzepatide 10 mg | minus 19.9 percent | minus 2.6 points |
| Eloralintide 9 mg plus tirzepatide 15 mg | minus 23.3 percent | minus 2.9 points |
| Placebo | minus 3.0 percent | minus 0.3 points |
Three things stand out. First, eloralintide alone lost less weight here, 8.2 to 12.3 percent, than the 17.6 to 20.1 percent seen at 6 and 9 mg in people without diabetes, which fits a pattern across weight loss drugs where results in type 2 diabetes run lower. Second, the dose response is flat: 6 mg did slightly better than 9 mg, though each arm is small. Third, eloralintide alone did not beat tirzepatide 15 mg alone on weight.
The headline combination arm, 23.3 percent, paired the highest eloralintide dose with the highest tirzepatide dose and is compared with tirzepatide 15 mg at 14.8 percent. The primary endpoint was the combination against placebo, and the comparison with tirzepatide alone was secondary. Lilly did not report placebo adjusted differences or statistics for the individual arms in its release.
Tolerability is the weak spot in what has been released. Lilly said gastrointestinal events were the most common, generally mild or moderate, mostly during dose escalation, and more frequent in the combination arms. It gave discontinuation due to adverse events as ranges only: 10.8 to 27.0 percent across the combination arms, 0 to 10.8 percent with eloralintide alone, 2.9 percent with tirzepatide alone and 16.7 percent with placebo. The placebo figure is unusually high, and the release does not explain the reasons for stopping. Nausea and vomiting rates by arm were not reported. Lilly plans phase 3 trials of the combination in the fourth quarter of 2026, using what it calls an optimized escalation schedule. The combination is a separate investigational product, and nothing in this entry establishes its dosing or safety. Two of those phase 3 trials are now registered as AMPLIFY-1 and AMPLIFY-2, covered in the next section.
Phase 3 for the combination: AMPLIFY-1 and AMPLIFY-2
Two phase 3 trials of eloralintide combined with tirzepatide are registered on ClinicalTrials.gov. Both are sponsored by Eli Lilly. AMPLIFY-2 is now listed as recruiting, with a start date of October 16, 2026 that the registry marks as actual, and AMPLIFY-1 is still listed as not yet recruiting. The registry’s official titles name the study drug LY900043, and the short titles and summaries call it EloraTZP, a coformulation of eloralintide and tirzepatide, the same combination described in the phase 2b section above.
| Trial | Who it enrolls | Compared with | Planned enrollment | Listed timing |
|---|---|---|---|---|
| AMPLIFY-1 (NCT07881432) | Adults with obesity and a BMI of 35 or more, without diabetes | Tirzepatide, eloralintide and placebo | 2,115 | Not yet recruiting; start December 2026, primary completion October 2029 |
| AMPLIFY-2 (NCT07881458) | Adults with obesity or overweight (BMI of 27 or more) and type 2 diabetes | Tirzepatide | 1,000 | Recruiting; started October 16, 2026, primary completion October 2029 |
Both trials use percent change in body weight at week 100 as the primary endpoint, and the registry says participation lasts about two years. AMPLIFY-2 tests the combination against tirzepatide alone in people with type 2 diabetes, the group in which the phase 2b trial reported the 23.3 percent figure. AMPLIFY-1 adds eloralintide alone and placebo as comparators in people without diabetes, which would let the trial separate what each component contributes.
Three limits apply. These are registry entries, which show what the sponsor intends to run and are not results. Neither record lists a dose of eloralintide or tirzepatide or an escalation schedule, and each gives the route only as subcutaneous, so nothing in them adds to the dosing picture, and the sponsor has described its schedule only in general terms. On its 29 October 2026 earnings call, Lilly said the phase 3 trials will use a slower, optimized dose escalation schedule, without giving amounts or step lengths. Lilly’s wider pipeline and what it has said lately are collected in the Eli Lilly tracker on The Weight Loss Atlas. AMPLIFY-2 is listed as recruiting at one of its 75 sites, the Los Angeles Institute for Metabolic Research, and the registry still shows the other 74 as not yet recruiting. AMPLIFY-1 has not opened. A recruiting status shows enrollment has begun, not when a first participant was dosed, and design details can still change. The earliest listed primary completion is October 2029.
What has not reported yet
Six phase 3 studies carrying ENLIGHTEN acronyms are registered, across obesity, type 2 diabetes, sleep apnoea, knee osteoarthritis and obesity persisting on a weekly incretin, 8,615 participants in total. None has reported and the earliest primary completion is January 2028. The newest, ENLIGHTEN-10, compares eloralintide with placebo in adults with obesity or overweight, type 2 diabetes and increased cardiovascular risk. The registry lists 3,000 planned participants, a start in December 2026 and primary completion in November 2029, and shows it as not yet recruiting. The acronyms run 1, 2, 3, 4, 6 and 10, so a page citing an ENLIGHTEN-5 is citing nothing.
Separately from the phase 3 program, the registry lists a phase 1 pharmacology study, NCT07935304, in 90 healthy adults aged 18 to 65 with a BMI of 23 to 40. It is open label and compares where a single subcutaneous dose is injected, and it also measures how the body handles one intravenous dose, with the area under the concentration curve and the peak concentration as the main measures through Day 57. The record shows it as not yet recruiting, with a start in November 2026, primary completion in April 2027, and sites in Salt Lake City and Singapore. It lists no dose amounts and no results. Evidence label: registered human trial without published results (Tier 2). It tests absorption, not whether the drug works.
The type 2 diabetes phase 2 trial has reported only as a conference presentation, described above. A journal publication with arm level adverse event data has not appeared. The AMPLIFY-1 and AMPLIFY-2 combination trials are separate from the ENLIGHTEN program and have not reported either; their earliest listed primary completion is October 2029.
A dated list of what is expected next for eloralintide, with the source for each date, is on its card on the Weight Loss Atlas pipeline tracker.
What circulates, and why no numbers appear here
Grey market vendors sell vials labelled eloralintide, commonly 1 mg or 10 mg, under research use framing. Whatever is in them is not the sponsor’s investigational product, and with no published sequence nobody can confirm it. There is no lawful compounding route either: not a component of an approved drug, no USP monograph, not on the FDA bulk substances list.
This site does not reproduce the circulating figures for this compound, because the compound is unapproved, the escalation is where the harm sits, and nothing verifies that the vials contain what the label says.
Community reference: Eloralintide Research, an independent information site that grades claims by evidence tier and says it is not affiliated with Eli Lilly. Its operator is not named, it is not clinical evidence, and it also carries a page about where to buy research-use material, which this site does not endorse.
What the record gets wrong
That it is approved or available. It is neither, and no application has been filed anywhere, yet grey market vendors sell it, and at least one supplier catalogue files it under a GLP-1 heading. That is the wrong class entirely: it has no reported activity at the GLP-1, GIP or glucagon receptor.
That it is a cagrilintide analogue. It is not. Different sponsor, different receptor profile, and a half life of roughly 13 to 15 days against 6.6 to 8.1. Cagrilintide is the compound eloralintide was designed to differ from. The conflation propagates into dose claims, with cagrilintide 2.4 mg presented as an eloralintide amount.
That eloralintide with tirzepatide produces figures in the high twenties. Figures like that circulated from abstracts released ahead of EASD 2026. The data actually presented, in people with type 2 diabetes, top out at 23.3 percent for the highest dose pairing, against 14.8 percent for tirzepatide 15 mg alone, and this entry has not verified anything higher. The combination, which Lilly calls eloraTZP, is a distinct investigational product from eloralintide alone and is not covered by the dosing or safety data in this entry.
Where the class stands
Pramlintide, approved as Symlin in 2005, is the only amylin analogue ever approved, and all its US formulations are discontinued with no approved generic. Cagrilintide reaches regulators only as part of CagriSema, filed with the FDA in December 2025 and not approved. Amycretin has been renamed zenagamtide, so entries comparing eloralintide to both double count one competitor. Which leaves the fact that frames this page: no amylin based product is currently marketed anywhere.
The newest amylin candidates, including Roche and Zealand’s petrelintide, are set side by side in the petrelintide vs eloralintide vs cagrilintide comparison.
Pfizer is pairing its own amylin analog with berobenatide, a once-monthly GLP-1 receptor agonist now in Phase 3 obesity trials. The berobenatide entry covers that program and what has been reported.
Ascletis, a Hong Kong company, is benchmarking an oral small-molecule amylin agonist, ASC39, against eloralintide. On 11 November 2026 it said it had submitted an FDA application to start human testing of a once-daily tablet that pairs ASC39 with its oral GLP-1 agonist ASC30 (Ascletis press release, 11 November 2026). The evidence so far is company-reported rat and receptor-assay data, including 6.6% placebo-adjusted weight loss in rats after six days against 5.6% for eloralintide, and there are no human data for the combination. The figures are laid out in the Eloralintide Research news item on the filing.
Frequently asked questions
What is eloralintide?
An investigational, once-weekly injectable amylin analogue from Eli Lilly, designed to be more selective for the amylin receptor than cagrilintide. It is not approved anywhere.
How does it work?
It activates amylin receptors more selectively than cagrilintide, engaging the calcitonin receptor component less strongly, a design intended to reduce nausea while keeping weight-loss efficacy. Whether that design goal is actually achieved is not clearly supported by the phase 2 tolerability data.
What dosage has been studied?
Phase 2 tested 1, 3, 6 and 9 mg once weekly, plus two escalation schedules reaching 9 mg, over 48 weeks. Phase 1 tested a wider range up to 12 mg. There is no approved or established dose.
Does it really cause less nausea than cagrilintide?
The evidence does not clearly support that. In the phase 2 trial, nausea reached 64 percent in one dose arm, at or above the rate reported for cagrilintide 2.4 mg monotherapy, which is the drug eloralintide was designed to improve on.
What dosage commonly circulates online?
This site does not reproduce circulating dosage figures for eloralintide. It is unapproved, its exact chemical sequence has never been published by the developer, and nothing sold under this name outside a clinical trial can be verified as the real compound.
Has it been studied in humans?
Yes, in phase 1 and phase 2 trials in obesity, with a phase 2 diabetes trial presented at EASD 2026 as conference data and five separate phase 3 trials registered. None of the phase 3 trials has reported results, with the earliest expected in 2028. Two further phase 3 trials of the eloralintide and tirzepatide combination, AMPLIFY-1 and AMPLIFY-2, are registered. AMPLIFY-2 is listed as recruiting and AMPLIFY-1 as not yet recruiting.
What did the type 2 diabetes trial show?
In a 367 person phase 2b trial presented at EASD 2026, eloralintide alone produced 8.2 to 12.3 percent weight loss and 1.1 to 1.4 points of HbA1c reduction at 48 weeks on the efficacy estimand. Combined with tirzepatide at the top doses it reached 23.3 percent, against 14.8 percent for tirzepatide 15 mg. The data come from a sponsor press release and have not been peer reviewed.
What are AMPLIFY-1 and AMPLIFY-2?
They are two phase 3 trials, registered by Eli Lilly, of eloralintide combined with tirzepatide, a product the registry calls EloraTZP. AMPLIFY-1 plans 2,115 adults with obesity and no diabetes, and AMPLIFY-2 plans 1,000 adults with type 2 diabetes. Both measure weight change at week 100 and report no dose levels, so they establish no dosing. AMPLIFY-2 is listed as recruiting and AMPLIFY-1 as not yet recruiting.
Is it the same as cagrilintide?
No. They are different molecules from different companies with different receptor-binding profiles and half-lives. Dosing figures for one should never be assumed to apply to the other.
Is eloralintide related to LY4086940?
They are separate Lilly compounds. Eloralintide is an amylin analog. LY4086940 is a different code that appears in two registered trials, both of which include oral dosing. Our LY4086940 write-up covers what those records show.
What side effects have been reported?
Gastrointestinal effects (nausea, in particular) at rates that varied widely and non-linearly by dose in the phase 2 trial, plus an unusual and unexplained drop in resting heart rate. No amylin receptor agonist of any kind has completed a cardiovascular outcomes trial.
What remains unknown?
Whether its selectivity design actually reduces side effects meaningfully in people, full discontinuation and vomiting rates from its own phase 2 trial (posted but not retrievable for this entry), effects in type 2 diabetes, long-term safety, and what the heart-rate reduction means clinically.
Bottom line
Eloralintide is a real, actively developed amylin analogue with a genuine weight-loss effect and a scientifically reasonable rationale for improved tolerability. But its own trial data do not clearly deliver on that rationale: nausea rates at some doses matched or exceeded the drug it was designed to be gentler than, and the sponsor’s own paper acknowledges there is no established way to define how selective is selective enough. It is not approved anywhere, its exact molecular sequence remains undisclosed, and every phase 3 trial needed to establish its real-world profile is still years from reporting. The first type 2 diabetes data, presented at EASD 2026 but not yet peer reviewed, show 8.2 to 12.3 percent weight loss with eloralintide alone and 23.3 percent when the top dose was combined with tirzepatide 15 mg. The combination has two registered phase 3 trials, AMPLIFY-1 and AMPLIFY-2, which have no results. AMPLIFY-2 is listed as recruiting and AMPLIFY-1 as not yet recruiting.
Sources
- Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2025; 406(10520): 2631 to 2643. Human phase 2 RCT, n=263, and the source of the week 48 efficacy estimand figures and the nausea and fatigue rates by arm. The abstract does not give discontinuation rates, vomiting by arm, serious adverse events or responder rates. PMID 41207310
- Bhattachar S, Tham LS, Tidemann-Miller B, et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: phase 1 proof of concept. Diabetes Obes Metab 2026; 28(4): 2651 to 2660. Human phase 1b multiple ascending dose, n=100 over 12 weeks. Source of the gastrointestinal rates by dose, the pulse rate reductions, bone marker stability and the steady state pharmacokinetics. PMID 41559929
- Briere DA, Qu H, Lansu K, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: from discovery to clinical proof of concept. Mol Metab 2025; 102: 102271. Mixed preclinical and human phase 1 single ascending dose. The only source of the structural description, the human and rat receptor pharmacology, the rat conditioned taste avoidance comparison and the sponsor caveats on selectivity thresholds. PMID 41109426
- Fischer SL, Borner T. Beyond GLP-1: amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs. Pharmacol Res 2026; 232: 108382. Review, mixed human and preclinical. Treats the tolerability question as an unresolved mechanistic problem and keeps the selectivity claim conditional. PMID 42586227
- Sigalov A, Frishman WH. Cardiometabolic risk reduction through selective amylin receptor agonism: emerging cardiovascular implications of eloralintide. Cardiol Rev 2026. Review of human phase 1 and 2 plus preclinical. Source for the pulse rate contrast against GLP-1 receptor agonists and for the statement that no amylin receptor agonist has been evaluated in a cardiovascular outcomes trial. PMID 42745233
- Bailey CJ, Flatt PR, Conlon JM. Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. Peptides 2026; 196: 171480. Review, mixed. Best source for the pramlintide history and the state of the amylin class. PMID 41747885
- Alhazmi A, le Roux CW. Amylin analogs: the next major class of weight loss therapy. Diabetes Obes Metab 2026. Narrative review current to 30 April 2026. Confirms the renaming of amycretin to zenagamtide and maps the competing molecules. PMID 42452898
- Eli Lilly and Company. A study of eloralintide in adults with obesity or overweight, n=263, 48 weeks, conducted under master protocol W8M-MC-CWMM. Human phase 2. The registry flags results as posted; they were not retrievable for this entry. NCT06230523
- Eli Lilly and Company. Single and multiple ascending dose study of LY3841136, total enrolment 148 across both parts. Human phase 1, published as Briere 2025 and Bhattachar 2026. NCT05295940
- Eli Lilly and Company. A study of LY3841136 and tirzepatide alone or in combination in adults with obesity or overweight and type 2 diabetes, n=367, primary endpoint percent change in body weight at week 48. Human phase 2b. Results presented at EASD 2026 on 30 September 2026 as a conference presentation, not yet published in a journal. NCT06603571
- Eli Lilly and Company. Phase 3 study of eloralintide in adults with obesity or overweight and type 2 diabetes, n=1,035, started 15 December 2025. Human phase 3, no results, the earliest primary completion in the programme at January 2028. NCT07282600
- Eli Lilly and Company. Phase 3 study of eloralintide in adults with obesity or overweight without type 2 diabetes, n=1,980, primary completion March 2028. Human phase 3, no results. Its secondary endpoints include percent change in total body fat mass, the first human test of the preferential fat mass loss seen in rats. NCT07321886
- Eli Lilly and Company. Announcement of phase 2 results for eloralintide in adults with obesity or overweight, 6 November 2025. Sponsor communication, not peer reviewed. Source of the one decimal weight change figures by arm and of the explicit definition of the efficacy estimand. Eli Lilly release, 6 November 2025
- Eli Lilly and Company. Public explainer on eloralintide, accessed September 2026. Sponsor communication. States that eloralintide is an investigational medication and that any potential submission for regulatory review depends on the outcomes of ongoing and future clinical trials. Eli Lilly explainer, accessed September 2026
- Eli Lilly and Company. EloraTZP, a combination of eloralintide and tirzepatide, compared with tirzepatide 15 mg in adults with obesity or overweight and type 2 diabetes, phase 2b, n=367, presented at EASD 2026. Sponsor press release, not peer reviewed. Source of the arm level weight and HbA1c figures on the efficacy estimand, the baseline values, the discontinuation ranges and the plan for phase 3 in the fourth quarter of 2026. Eli Lilly release, 30 September 2026 (NCT06603571)
- Eloralintide Research. Independent information site on eloralintide (LY3841136) that grades claims by evidence tier and states it is not affiliated with Eli Lilly. Operator not named. Community resource, not clinical evidence, listed so readers can compare it with this entry. The site also carries a page about where to buy research-use material, which this entry does not endorse or rely on. eloralintideresearch.com, operator not named
- Phase 3, eloralintide and tirzepatide coformulation (EloraTZP; the official title names LY900043) versus tirzepatide, eloralintide and placebo in adults with obesity and a BMI of 35 or more, without diabetes. Sponsor Eli Lilly and Company. The registry lists planned enrollment of 2,115, start December 2026, primary completion October 2029, primary outcome percent change in body weight at week 100, status not yet recruiting, and no posted results. Human. NCT07881432
- Phase 3, EloraTZP versus tirzepatide in adults with type 2 diabetes and obesity or overweight (BMI of 27 or more). Sponsor Eli Lilly and Company. The registry lists planned enrollment of 1,000, a start of October 16, 2026 that it marks as actual, primary completion October 2029, primary outcome percent change in body weight at week 100, status recruiting, and no posted results. Human. NCT07881458
- Phase 3, ENLIGHTEN-10, once weekly eloralintide versus placebo in adults with obesity or overweight, type 2 diabetes and increased cardiovascular risk. Sponsor Eli Lilly and Company. The registry lists planned enrollment of 3,000, start December 2026, primary completion November 2029, primary outcomes percent change in body weight at week 64 and change in HbA1c at week 36, status not yet recruiting, and no posted results. Human. NCT07900633
- Eli Lilly and Company, third-quarter 2026 earnings call, 29 October 2026, remarks by Dan Skovronsky. Management commentary, not a registry update or publication. Source of the statement that phase 3 EloraTZP trials will use a slower, optimized dose escalation schedule and of the remark that eloralintide alone had adverse-event discontinuations lower than placebo. Read from a third-party transcript copy. Eli Lilly Q3 2026 earnings call (third-party transcript copy)
Live registry status
These are the registered trials this page cites, pulled from ClinicalTrials.gov and refreshed automatically. Status and dates are what the registry currently shows. Listing a trial here does not mean it produced a positive result.
Compare Eloralintide with related compounds
Research area: Metabolic and incretin.